Modulation of oncogenic potential by alternative gene use in human prostate cancer

Nature Medicine

Volumn 5, Issue 3, 1999, Pages 275-279

  Kadkol, Shrihari S ^a   Brody, Jonathan R ^a   Pevsner, Jonathan ^a,b   Bai, Jining ^a   Pasternack, Gary R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOPROTEIN;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL TRANSFORMATION; GENE EXPRESSION; GENE SEQUENCE; GENE THERAPY; GENETIC TRANSCRIPTION; GENETIC TRANSFORMATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECIES DIFFERENTIATION;

ALTERNATIVE SPLICING; HUMANS; MALE; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 0033054167     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/6488     Document Type: Article

References (17)

1. Isaacs, W.B. et al Genetic alterations in Prostate Cancer. Cold Spring Harbor Symposia on Quantitative Biology 59, 653-659 (1994).
2. Fleming, W.H., Hamel, A., McDonald, R. & Ramsey, E. Expression of c-myc proto-oncogene in human prostate carcinoma and BPH. Cancer Res. 46, 1535-1538 (1985).
3. Kadkol, S.S., Brody, J.R., Epstein, J.I., Kuhajda, F.P. & Pasternack, G.R. Novel nuclear phosphoprotein pp32 is highly expressed in intermediate-and high-grade prostate cancer. The Prostate 34, 231-237 (1998).
4. Chen, T.H. et al. Structure of pp32, an acidic nuclear protein which inhibits oncogene-induced formation of transformed foci. Mol. Biol. Cell 7, 2045-2056 (1996).
5. Malek, S.N., Katumuluwa, A.I. & Pasternack, G.R. Identification and preliminary characterization of two related proliferation-associated nuclear phosphoproteins. J. Biol. Chem. 265, 13400-13409 (1990).
6. Walensky, L.D., Coffey, D.S., Chen, T.H., Wu, T.C. & Pasternack GR. A novel M(r) 32,000 nuclear phosphoprotein is selectively expressed in cells competent for self-renewal. Cancer Res. 53, 4720-41726 (1993).
7. Land, H., Parada L.F. & Weinberg, R.A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596-602 (1993).
8. Smith TF and Waterman M. Identification of common molecular subsequences. J. Mol. Biol. 147, 195-197 (1981).
9. Vaesen, M. et al. Purification and characterization of two putative HLA class II associated proteins: PHAPI and PHAPII. Biol. Chem. 375, 113-126 (1994).
10. Fink, T.M., Vaesen, M., Kratzin, H.D., Lichter, P. & Zimmer, M. Localization of the gene encoding the putative human HLA class II-associated protein (PHAPI) to chromosome 15q22.3-q23 by fluorescence in situ hybridization. Genomics 29, 309-310 (1995).
11. Li, M., Makkinje, A. & Damuni, Z. Molecular Identification of 11PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A. Biochemistry 35, 6998-7002 (1996).
12. Ulitzur, N., Rancano, C. & Pfeffer, S.R. Biochemical characterization of mapmodulin, a protein that binds microtubule-associated proteins. J. Biol. Chem. 272, 30577-30582 (1997).
13. Matsuoka, K. et al. A nuclear factor containing the leucine-rich repeats expressed in murine cerebellar neurons. Proc. Natl. Acad. Sci. USA 91, 9670-9674 (1994).
14. Mencinger, M., Panagopoulos, I., Contreras, J.A., Mitelman, F. & Aman, P. Expression analysis and chromosomal mapping of a novel human gene, APRIL, encoding an acidic protein rich in leucines. Biochim. Biophys. Acta 1395, 176-180 (1998).
15. Drwinga, H.L., Toji, L.H., Kim, C.H., Greene, A.E. & Mulivor, R.A. NIGMS human/rodent somatic cell hybrid mapping panels 1 and 2. Genomics 16, 311-314 (1993).
16. Cattoretti, G. et al. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J. Pathol. 171, 83-98 (1993).
17. Gusev, Y. et al. pp32 overexpression induces nuclear pleomorphism in rat prostatic carcinoma cells. Cell Prolif. 29, 643-653 (1996).